Invasive Aspergillosis Clinical Trial
Official title:
An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects
Study of interactions between F901318 and multiple doses of posaconazole and pantoprazole and single doses of cyclosporine A and tacrolimus in healthy subjects. Pharmacokinetic (PK) profiles, safety and tolerability will be assessed.
Open label randomised parallel group evaluation of three or four dosing schedules over a
period of 21 days. Subjects will be randomised into the groups as follows:
1. Cohort A: Pre-treat with tacrolimus 2 mg on day -9 and cyclosporine A 100 mg on Day -3
and obtain pharmacokinetic (PK) curves for both compounds prior to dosing with F901318.
Then, F901318 360 mg b.i.d. for 1 or two days followed by 240 mg b.i.d. for 18 or 19
days (Days 2 or 3-20) and 240 mg o.m. on Day 21 (n=12, ideally 6 females minimum 3
females, 6 males, maximum 9 males). Dose again with tacrolimus on Day 9 and with
cyclosporine A on day 16 and obtain full PK curves.
2. Cohort B: F901318 360 mg b.i.d. for 1 or 2 days followed by 240 mg b.i.d. for 5 or 6
days. On Day 8, add posaconazole tablets 300 mg b.i.d. followed by 300 mg daily for 6
days (Days 9-14) and decrease F901318 dose to 120 mg daily from Day 8 onwards. On Day
15, discontinue posaconazole but continue F901318 for a further 6 days at a dose of 120
mg daily (Days 15 to 21) (n=12, ideally 6 females, 6 males).
3. Cohort C: F901318 360 mg b.i.d. for one or two days followed by 240 mg b.i.d for 19 days
(Day 1-20) and 240 mg o.m. on Day 21. On Day 8, add pantoprazole 40 mg daily for 7 days.
On Day 15, discontinue pantoprazole but continue F901318 240 mg b.i.d to day 20 and 240
mg o.m. on Day 21 (n=12, ideally 6 females, 6 males).
4. Cohort D (optional): F901318 for 21 days. Will be conducted, if necessary after
completion of cohorts A-C. Dose schedule to be determined on the basis of results from
ongoing study F901318-01-06-16 and cohort A of this study but could be up to 480 mg
b.i.d for up to three days followed by up to 360 mg bid for 17-19 days and up to 360
o.m. on Day 21 with the objective of achieving and maintaining C12 of 1µg/mL throughout
the dosing period (n=12, ideally 6 females, 6 males). The decision to proceed will be
taken based on QC'd pharmacokinetic data by the PI and representative(s) of the Sponsor.
Intensive PK evaluations of F901318 and metabolite and concomitant medications will occur as
follows:
- Day 1 (F901318 and metabolite alone)
- Day 7 (F901318 and metabolite alone)
- Day 14 (F901318 and metabolite and posaconazole cohort B)
- Day 21 (F901318 and metabolite)
Peak and trough levels of F901318 and metabolite (and posaconazole in cohort B on Days 8-20)
will be obtained on intermediate days.
PK curves for tacrolimus will be obtained from Day -9 to Day -3 and from Day 9 to Day 15
(cohort A)
PK curves for cyclosporine A will be obtained from Day -3 to Day 1 (prior to dosing with
F901318) and from Day 18 to Day 21 (cohort A)
Adverse events and 12 lead ECGs will be recorded and blood and urine samples will be obtained
for safety evaluation throughout.
All subjects will return for a post-study visit 8 to 10 days after the last dose of study
medication.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis:a Real-word Study
|
||
Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 | |
Completed |
NCT04550936 -
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
|